HDAC6 and Ovarian Cancer

被引:27
|
作者
Haakenson, Joshua [1 ]
Zhang, Xiaohong [1 ,2 ]
机构
[1] Univ S Florida, Morsani Coll Med, Dept Pathol & Cell Biol, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Mol Oncol, Tampa, FL 33612 USA
关键词
HDAC6; ovarian cancer; cancer-related signaling pathways; inhibitors; cell stress response; motility; oncogenesis; histone deacetylase; HISTONE DEACETYLASE 6; REGULATES AGGRESOME FORMATION; 2 CATALYTIC DOMAINS; CELL-MIGRATION; MICROTUBULE ACETYLATION; GLUCOCORTICOID-RECEPTOR; STRESS GRANULES; PROTEIN; TUBULIN; INHIBITORS;
D O I
10.3390/ijms14059514
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The special class IIb histone deacetylase, HDAC6, plays a prominent role in many cellular processes related to cancer, including oncogenesis, the cell stress response, motility, and myriad signaling pathways. Many of the lessons learned from other cancers can be applied to ovarian cancer as well. HDAC6 interacts with diverse proteins such as HSP90, cortactin, tubulin, dynein, p300, Bax, and GRK2 in both the nucleus and cytoplasm to carry out these cancerous functions. Not all pro-cancer interactions of HDAC6 involve deacetylation. The idea of using HDAC6 as a target for cancer treatment continues to expand in recent years, and more potent and specific HDAC6 inhibitors are required to effectively down-regulate the tumor-prone cell signaling pathways responsible for ovarian cancer.
引用
收藏
页码:9514 / 9535
页数:22
相关论文
共 50 条
  • [31] QSAR Analysis of HDAC6 Inhibitors
    O. V. Tinkov
    V. Yu. Grigorev
    L. D. Grigoreva
    Moscow University Chemistry Bulletin, 2022, 77 : S25 - S35
  • [32] A role for HDAC6 in leptin sensitivity
    Claire Greenhill
    Nature Reviews Endocrinology, 2022, 18 : 194 - 194
  • [33] HDAC6: Physiological function and its selective inhibitors for cancer treatment
    Yang, Penghui
    Zhang, Lei
    Zhang, Yingjie
    Zhang, Jian
    Xu, Wenfang
    DRUG DISCOVERIES AND THERAPEUTICS, 2013, 7 (06): : 233 - 242
  • [34] High expression of HDAC6 correlates with poor prognosis in colon cancer
    Xu, Li
    Liu, Yi
    Xia, Yabin
    Huang, Xiaoxu
    Hu, Kaifeng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (04): : 4505 - 4512
  • [35] Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer
    Guerra, Fabiana Selos
    Rodrigues, Daniel Alencar
    Fraga, Carlos Alberto Manssour
    Fernandes, Patricia Dias
    PHARMACEUTICALS, 2021, 14 (05)
  • [36] Inhibition of HDAC6 Activity Protects Against Endothelial Dysfunction and Atherogenesis in vivo: A Role for HDAC6 Neddylation
    Nomura, Yohei
    Nakano, Mitsunori
    Woo Sung, Hyun
    Han, Mingming
    Pandey, Deepesh
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [37] Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis
    Jiang, Dandan
    Ma, Peizhi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Targeting HDAC6 to reduce the aggressiveness of metastatic breast cancer in immunotherapy
    Banik, Debarati
    Hadley, Melissa
    Palmer, Erica
    Gallub, Vincent
    Sotomayor, Eduardo
    Kozikowski, Alan
    Villagra, Alejandro
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells
    Kamemura, Kazuo
    Ito, Akihiro
    Shimazu, Tadahiro
    Matsuyama, Akihisa
    Maeda, Satoko
    Yao, Tso-Pang
    Horinouchi, Sueharu
    Khochbin, Saadi
    Yoshida, Minoru
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 374 (01) : 84 - 89
  • [40] Advances in dual-targeting inhibitors of HDAC6 for cancer treatment
    Gu, Zhicheng
    Lin, Shuxian
    Yu, Junhui
    Jin, Fei
    Zhang, Qingqing
    Xia, Keli
    Chen, Lei
    Li, Yan
    He, Bin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 275